8. Huntington disease
197 clinical trials, 171 drugs (DrugBank: 54 drugs), 82 drug target genes, 144 drug target pathways
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-002822-10-DE (EUCTR) | 11/12/2020 | 06/11/2020 | A study of Pridopidine in Patients with Early Stage of Huntington Disease | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease - PRidopidine Outcome on Function in Huntington Disease (PROOF-HD) | Huntington Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: PL101 INN or Proposed INN: PRIDOPIDINE HYDROCHLORIDE Other descriptive name: Pridiopidine | Prilenia Neurotherapeutics Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 480 | Phase 3 | United States;European Union;Canada;Germany;United Kingdom | ||
| 2 | NCT04556656 (ClinicalTrials.gov) | October 16, 2020 | 14/9/2020 | PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease | Huntington Disease | Drug: Pridopidine;Drug: Placebo | Prilenia | NULL | Recruiting | 25 Years | N/A | All | 480 | Phase 3 | United States |
| 3 | NCT03019289 (ClinicalTrials.gov) | April 19, 2017 | 3/1/2017 | A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease | A Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease | Health Volunteers, Huntington Disease | Drug: pridopidine (90 mg) | Prilenia | NULL | Completed | 25 Years | N/A | Male | 23 | Phase 1 | Germany |
| 4 | EUCTR2015-000904-24-NL (EUCTR) | 15/02/2016 | 17/02/2016 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Germany;Netherlands;Italy;United Kingdom | ||
| 5 | EUCTR2015-000904-24-DE (EUCTR) | 03/12/2015 | 04/08/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Poland;Austria;Australia;France;United States;Canada;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2015-000904-24-AT (EUCTR) | 18/11/2015 | 15/09/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 19.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;United States;Canada;Poland;Denmark;Australia;Austria;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 7 | EUCTR2015-000904-24-GB (EUCTR) | 13/11/2015 | 18/08/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;United States;Canada;Poland;Austria;Australia;Russian Federation;Netherlands;Germany;Italy;United Kingdom | |||
| 8 | NCT02494778 (ClinicalTrials.gov) | September 24, 2015 | 7/7/2015 | A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD) | Huntington's Disease | Drug: Pridopidine | Prilenia | NULL | Terminated | 21 Years | N/A | All | 248 | Phase 2 | United States;Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;Denmark |
| 9 | EUCTR2015-000904-24-IT (EUCTR) | 15/09/2015 | 23/02/2018 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington's Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidina Product Code: TV-7820 INN or Proposed INN: Pridopidina Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidina Product Code: TV-7820 INN or Proposed INN: Pridopidina Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Italy | ||
| 10 | EUCTR2013-001888-23-DK (EUCTR) | 13/04/2015 | 08/01/2015 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Denmark;Australia;Germany;Netherlands | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2013-001888-23-PL (EUCTR) | 23/07/2014 | 14/05/2014 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 12 | EUCTR2013-001888-23-AT (EUCTR) | 01/07/2014 | 08/01/2014 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 13 | EUCTR2013-001888-23-NL (EUCTR) | 07/04/2014 | 20/12/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Netherlands;Germany | ||
| 14 | EUCTR2013-001888-23-DE (EUCTR) | 25/03/2014 | 10/12/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 15 | EUCTR2013-001888-23-IT (EUCTR) | 13/03/2014 | 11/12/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Australia;Denmark;Netherlands;Germany | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02006472 (ClinicalTrials.gov) | February 28, 2014 | 5/12/2013 | A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease | Huntington's Disease | Drug: Pridopidine;Other: Placebo | Prilenia | European Huntington's Disease Network;Huntington Study Group | Completed | 21 Years | N/A | All | 408 | Phase 2 | United States;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom |
| 17 | EUCTR2013-001888-23-GB (EUCTR) | 22/01/2014 | 27/11/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 18 | NCT01306929 (ClinicalTrials.gov) | March 1, 2011 | 28/2/2011 | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease | A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART). | Huntington Disease | Drug: pridopidine | Prilenia | NULL | Completed | N/A | N/A | All | 235 | Phase 2 | United States;Canada |
| 19 | NCT00724048 (ClinicalTrials.gov) | October 2008 | 24/7/2008 | A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease | A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART) | Huntington Disease | Drug: ACR16 10 mg;Drug: ACR16 22.5 mg;Drug: ACR16 45 mg;Other: Placebo | Teva Pharmaceutical Industries | NULL | Completed | 30 Years | N/A | Both | 227 | Phase 2;Phase 3 | United States;Canada |
| 20 | NCT00665223 (ClinicalTrials.gov) | April 2008 | 22/4/2008 | A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease | A Multicentre, Multinational, Randomized, Double-blind, Parallel-group Study Comparing ACR16 Versus Placebo for the Symptomatic Treatment of Huntington's Disease | Huntington's Disease | Drug: ACR16;Drug: Placebo | Teva Pharmaceutical Industries | NULL | Completed | 30 Years | N/A | Both | 437 | Phase 3 | Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom |